BioMarin Pharmaceutical Inc. provided financial guidance for 2023. For the period, the company expects Total Revenues to be $2,375 million to $2,500 million. GAAP Net Income $155 million to $205 million.
GAAP Diluted EPS $0.78 to $1.03.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
79.7 USD | -0.99% | -3.41% | -17.27% |
BioMarin Pharmaceutical Inc. provided financial guidance for 2023. For the period, the company expects Total Revenues to be $2,375 million to $2,500 million. GAAP Net Income $155 million to $205 million.
GAAP Diluted EPS $0.78 to $1.03.
1st Jan change | Capi. | |
---|---|---|
-17.27% | 15.29B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.40% | 32.81B | |
+52.41% | 25B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B | |
-7.48% | 7B |